focus -WSS

focus

author：focus 2025-09-30 00:37:47 - browse：8

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Today's health inequities arise from racist U.S. history, say experts

leisure time

WSS

How state and local governments are sidelining science

What health policies could hitch a ride on a spending bill?

It's time to get medical device identifiers over the finish line

What is STAT's opinion section for?

A new study sees potential in DNA sequencing of infants

Publishing genetic code of viruses could cause disaster

leisure time

focus

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Jerome Adams on the need for new antivirals for Covid

A new study sees potential in DNA sequencing of infants

How one medical school became remarkably diverse

It's time to get medical device identifiers over the finish line

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Petition to FDA: Get the lead out of consumer hair dyes

Anesthesiologist group: stop taking Ozempic before surgery

Palantir health business leans on meeting customers’ needs

focus

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Weight loss drugs should be covered by insurers, AMA says

Living with Fabry disease, a condition that causes chronic pain

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Publishing genetic code of viruses could cause disaster

Weight loss drugs should be covered by insurers, AMA says

leisure time

hotspot

hotspot

leisure time